CV Lattes
ResearcherID
ORCID
Secretaria da Saúde (São Paulo - Estado). Coordenadoria de Controle de Doenças (CCD). Instituto Adolfo Lutz (IAL) (Institutional affiliation for the last research proposal) Birthplace: Brazil
Bachelor in Pharmacy & Biochemistry (Oswaldo Cruz College, 1997), master's degree Institute of Energy and Nuclear Research -USP (1999), doctorate in Parasitology (Institute of Biomedical Sciences-USP) (2003) with sandwich period at the London School of Hygiene and Tropical Medicine (with Prof. Simon L. Croft). Post-doctorate at UNIFESP (Physiology). Professor and scientific researcher VI of the Adolfo Lutz Institute (2004-present), coordinator of the Laboratory of Novel Drugs for Neglected Diseases and deputy director of the Parasitology and Mycology Centre. Professor (2006-current) and deputy general coordinator of the Postgraduation Program of the State Department of Health and coordinator of the Laboratory Research in Public Health area. Professor (2010-current) at the postgraduation program of Institute of Tropical Medicine, Faculty of Medicine University of São Paulo. Expertise 1) drugs for infectious diseases, with an emphasis on neglected tropical diseases such as leishmaniasis and Chagas disease; 2) drugs for multidrug-resistant pathogens (ESKAPE); 3) Marine Microbiology with emphasis on the OSMAC approach and isolation of microbial metabolites as pharmaceutical prototypes; 4) in vitro studies of mechanism of action and preclinical in vivo. Coordinate national and international collaborative projects, with UFABC, UNIFESP, USP`, University of Oxford (UK), University of Dundee (UK), University of Southampton (UK), University of Bangor (UK), London School of Hygiene and Tropical Medicine (United Kingdom), Universität Munster (DE), Johannes Gutenberg-University Mainz (DE), Universität Düsseldorf (DE), Ohio State University (USA). Coordinated public-private project with the pharmaceutical company GSK (UK 2011-2014). He is a member (2011-current) of the international research network on natural products for drugs (ResNet NPND- Universität Münster, DE). Editorial Board Member - Infectious Diseases - of the journal Scientific Reports (Nature). Ad hoc advisor of international agencies such as Research Councils (RCUK), Health Research Board (Ireland, United Kingdom), Agence Nationale de la Recherche (ANR-France), Conycit (Argentina), National Science Center (Poland). Production: publications: 112 (index H 28); supervision 10 (master's), 8 (doctorate), postdoctoral: 4 (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Considering the advancement of the COVID-19 pandemic, the World Health Organization (WHO) has warned of its strong impact on vulnerable populations affected by neglected parasitic diseases and coinfections with SARS-CoV-2. The WHO also warned that due to the increase in hospital admissions, it became evident the need to expand the chemotherapy arsenal to fight multiresistant bacteria. Con…
Neisseria gonorrhoeae (Ng, gonococcus) is the causative agent of the sexually transmitted disease gonorrhoea and affects 78 million people worldwide. Gonococcal infection is frequently asymptomatic but long-term and/or permanent sequelae can develop in individuals. Effective, accessible and affordable antimicrobial treatment is essential for management and control. However, gonococci have…
IAL has established itself as a reference institution in Public Health, developing scientific research and performing analytical procedures for diagnostic elucidation and sanitary control, rapidly addressing the demands of Health Surveillance of the different regions of the State of Sao Paulo and other units of the federation. The data regarding the IAL scientific-technical production (se…
Considering the morbidity and mortality of visceral leishmaniasis and Chagas' disease, and the therapeutic limitations, these neglected protozoan diseases have been prioritized by WHO. The present proposal aims the search for a new pharmaceutical prototype for each disease, through coordinated activities in Drug Discovery. Based in a multidisciplinary proposal, we propose the continuation…
Neglected protozoosis as leishmaniasis and Chagas disease, afflict more than 20 million people mainly in developing countries, with a limited, highly toxic and inefficient therapeutic arsenal. Using two approaches in Drug Discovery, as the drug repositioning and combination therapy, this proposal aims to study oral antidepressant drugs, with focus mainly on sertraline, as a potential alte…
Brazilian biodiversity has proved a powerful source of small bioactive molecules, which are valuable lead compounds for the development of useful therapeutics. Based ín these aspects, biodiversity conservation and restoration have been high priorities for ... (AU)
(Only some records are available in English at this moment)
Chagas disease affects about 8 million people, with only one drug approved in Brazil. Considering the therapeutic limitations of this protozoa, as well as the lack of interest from the private sector in investing in new therapies, there is a need for research into new drugs. Comprising a vast chemodiversity, marine microbial metabolites are one of the important sources of new anti-infecti…
Neglected protozoan diseases as Leishmaniasis and Chagas Disease affect more than 20 million people, mainly in developing countries. Considering the rstricted therapeutic arsenal, toxic and inefficient, new treatments are urgently needed. In the search for new compounds, natural metabolites represent a promising source of pharmaceutical prototypes. The present proposal aims to identify ne…
(Only some records are available in English at this moment)
The "One Strain Many Compounds" (OSMAC) approach is a cultivation-based strategy, which aims to provide a simple and promising tool, with the ability to stimulate the expression of cryptic genes in microorganisms. This approach highlights how a single microbial strain can produce different biomolecules when grown under different environmental conditions. Auxiliary metabolites by microorga…
Visceral leishmaniasis is a neglected disease that mainly affects developing countries. Available chemotherapy for the treatment of leishmaniasis has a reduced number of drugs, with severe adverse effects and progressive increase of resistance. Drug repositioning consists in the search for new uses for approved drugs and is a great opportunity to introduce new therapies by significantly r…
Neglected diseases cause more than 534,000 deaths annually and is prevalent mostly in poor/developing countries. Leishmaniasis fit this frame and cause approximately 2.1 million DALYs (disability-adjusted life year), expressed as the number of years lost due to ill health, disability or early death. Among the various clinical forms that the disease presents, this it is being dependent on …
(Only some records are available in English at this moment)
Leishmaniasis is a neglected tropical disease, which includes a diseases spectrum of varying degrees of severity, resulting from a skin lesion to a progressive fatal visceral infection. Estimated at 12 million cases, leishmaniasis affects 98 countries with a limited and toxic therapeutic arsenal. The development of new therapies for leishmaniasis is therefore essential. Liposomes have bee…
| 3 / 3 | Ongoing research grants |
| 11 / 10 | Completed research grants |
| 4 / 4 | Ongoing scholarships in Brazil |
| 8 / 7 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 27 / 25 | All research grants and scholarships |
| Associated processes | |